Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Cited In for PubMed (Select 21048008)

1.

Rapid Induction of High-Level Carbapenem Resistance in Heteroresistant KPC-Producing Klebsiella pneumoniae.

Adams-Sapper S, Nolen S, Donzelli GF, Lal M, Chen K, Justo da Silva LH, Moreira BM, Riley LW.

Antimicrob Agents Chemother. 2015 Jun;59(6):3281-9. doi: 10.1128/AAC.05100-14. Epub 2015 Mar 23.

PMID:
25801565
2.

Using genomics to standardize population analysis profile-area under the curve ratio for vancomycin-intermediate Staphylococcus aureus.

Read TD, Satola SW.

J Clin Microbiol. 2014 Oct;52(10):3824-6. doi: 10.1128/JCM.01536-14. Epub 2014 Jul 23. No abstract available.

3.

Dissecting vancomycin-intermediate resistance in staphylococcus aureus using genome-wide association.

Alam MT, Petit RA 3rd, Crispell EK, Thornton TA, Conneely KN, Jiang Y, Satola SW, Read TD.

Genome Biol Evol. 2014 Apr 30;6(5):1174-85. doi: 10.1093/gbe/evu092.

4.

Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey.

Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, Yalcin AN, Dündar DO, Topçu AW, Aksit F, Usluer G, Ozakin C, Akalin H, Hayran M, Korten V.

BMC Infect Dis. 2013 Dec 10;13:583. doi: 10.1186/1471-2334-13-583.

5.

Reduced vancomycin susceptibility in porcine ST9 MRSA isolates.

Kwok GM, O'Donoghue MM, Doddangoudar VC, Ho J, Boost MV.

Front Microbiol. 2013 Oct 25;4:316. doi: 10.3389/fmicb.2013.00316. eCollection 2013.

6.

Activities of vancomycin, ceftaroline, and mupirocin against Staphylococcus aureus isolates collected in a 2011 national surveillance study in the United States.

Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Crispell EK, Riahi F, McDanel JS, Satola SW, Doern GV.

Antimicrob Agents Chemother. 2014;58(2):740-5. doi: 10.1128/AAC.01915-13. Epub 2013 Nov 18.

7.

The effect of staphylococcal cassette chromosome mec (SCCmec) type on clinical outcomes in methicillin-resistant Staphylococcus aureus bacteremia.

Han JH, Edelstein PH, Bilker WB, Lautenbach E.

J Infect. 2013 Jan;66(1):41-7. doi: 10.1016/j.jinf.2012.09.001. Epub 2012 Sep 6.

8.

A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.

Passalacqua KD, Satola SW, Crispell EK, Read TD.

Antimicrob Agents Chemother. 2012 Oct;56(10):5212-23. doi: 10.1128/AAC.05770-11. Epub 2012 Jul 30.

9.

Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia.

Han JH, Mascitti KB, Edelstein PH, Bilker WB, Lautenbach E.

Antimicrob Agents Chemother. 2012 Oct;56(10):5164-70. doi: 10.1128/AAC.00757-12. Epub 2012 Jul 23.

10.

First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Chung DR, Baek JY, Kim HA, Lim MH, Kim SH, Ko KS, Kang CI, Peck KR, Lee NY, Song JH.

J Clin Microbiol. 2012 Jul;50(7):2513-4. doi: 10.1128/JCM.00590-12. Epub 2012 May 2.

11.

Methicillin-resistant Staphylococcus capitis with reduced vancomycin susceptibility causes late-onset sepsis in intensive care neonates.

Rasigade JP, Raulin O, Picaud JC, Tellini C, Bes M, Grando J, Ben Saïd M, Claris O, Etienne J, Tigaud S, Laurent F.

PLoS One. 2012;7(2):e31548. doi: 10.1371/journal.pone.0031548. Epub 2012 Feb 14.

12.

Spread of epidemic MRSA-ST5-IV clone encoding PVL as a major cause of community onset staphylococcal infections in Argentinean children.

Sola C, Paganini H, Egea AL, Moyano AJ, Garnero A, Kevric I, Culasso C, Vindel A; Study Group of CA-MRSA in Children, Argentina-2007, Lopardo H, Bocco JL.

PLoS One. 2012;7(1):e30487. doi: 10.1371/journal.pone.0030487. Epub 2012 Jan 23.

13.

Prior vancomycin use is a risk factor for reduced vancomycin susceptibility in methicillin-susceptible but not methicillin-resistant Staphylococcus aureus bacteremia.

Mascitti KB, Edelstein PH, Fishman NO, Morales KH, Baltus AJ, Lautenbach E.

Infect Control Hosp Epidemiol. 2012 Feb;33(2):160-6. doi: 10.1086/663708. Epub 2011 Dec 20.

14.

Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States.

Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV.

J Clin Microbiol. 2011 Dec;49(12):4203-7. doi: 10.1128/JCM.01152-11. Epub 2011 Oct 5.

15.

Predictors of relapse of methicillin-resistant Staphylococcus aureus bacteremia after treatment with vancomycin.

Welsh KJ, Skrobarcek KA, Abbott AN, Lewis CT, Kruzel MC, Lewis EM, Gardiner JM, Mohr JF, Armitige LY, Wanger A.

J Clin Microbiol. 2011 Oct;49(10):3669-72. doi: 10.1128/JCM.05287-11. Epub 2011 Aug 24.

16.

Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype.

Satola SW, Lessa FC, Ray SM, Bulens SN, Lynfield R, Schaffner W, Dumyati G, Nadle J, Patel JB; Active Bacterial Core surveillance (ABCs) MRSA Investigators.

J Clin Microbiol. 2011 Apr;49(4):1583-7. doi: 10.1128/JCM.01719-10. Epub 2011 Feb 16.

17.

Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates.

van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB.

J Clin Microbiol. 2011 Apr;49(4):1489-94. doi: 10.1128/JCM.02302-10. Epub 2011 Jan 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk